Inhibikase Therapeutics (IKT) Income from Continuing Operations (2020 - 2024)
Historic Income from Continuing Operations for Inhibikase Therapeutics (IKT) over the last 5 years, with Q4 2024 value amounting to -$12.9 million.
- Inhibikase Therapeutics' Income from Continuing Operations fell 19359.61% to -$12.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$28.6 million, marking a year-over-year decrease of 4230.65%. This contributed to the annual value of -$28.6 million for FY2024, which is 4230.64% down from last year.
- Per Inhibikase Therapeutics' latest filing, its Income from Continuing Operations stood at -$12.9 million for Q4 2024, which was down 19359.61% from -$5.8 million recorded in Q3 2024.
- Inhibikase Therapeutics' 5-year Income from Continuing Operations high stood at -$421869.0 for Q2 2020, and its period low was -$12.9 million during Q4 2024.
- Its 5-year average for Income from Continuing Operations is -$4.2 million, with a median of -$4.6 million in 2022.
- Per our database at Business Quant, Inhibikase Therapeutics' Income from Continuing Operations plummeted by 56674.67% in 2021 and then skyrocketed by 1857.13% in 2024.
- Over the past 5 years, Inhibikase Therapeutics' Income from Continuing Operations (Quarter) stood at -$1.2 million in 2020, then crashed by 317.36% to -$5.0 million in 2021, then rose by 14.02% to -$4.3 million in 2022, then decreased by 1.58% to -$4.4 million in 2023, then plummeted by 193.6% to -$12.9 million in 2024.
- Its Income from Continuing Operations stands at -$12.9 million for Q4 2024, versus -$5.8 million for Q3 2024 and -$5.1 million for Q2 2024.